Effect of Suhuang Zhike capsules combined with fluticasone propionate in the treatment of allergic rhinitis with cough variant asthma and its influences on VCAM-1 and HMGB1 levels
Objective To investigate the effect of Suhuang Zhike capsules combined with fluticasone propionate in the treatment of allergic rhinitis with cough variant asthma.Methods A total of 120 patients with allergic rhinitis and cough variant asthma admitted from March 2020 to June 2022 were selected as the research objects,and the patients were divided into control group and observation group by random number table method,with 60 cases in each group.The control group was treated with routine treatment+fluticasone propionate,and the observation group was treated with Suhuang Zhike capsules on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P＜0.05).Before treatment,there were no significant differences in fractional exhaled nitric oxide(FeNO),eosinophil granulocyte(Eos)and Asthma Control Test(ACT)score between the two groups(P＞0.05);after treatment,the FeNO,Eos in the observation group were lower than those in the control group,and the ACT score was higher than that in the control group(P＜0.05).Before treatment,there were no significant differences in the expression levels of vascular cell adhesion molecule-1(VCAM-1)and high mobility group protein B1(HMGB1)between the two groups(P＞0.05);after treatment,the expression levels of VCAM-1 and HMGB1 in the observation group were lower than those in the control group(P＜0.05).Conclusion Suhuang Zhike capsules combined with fluticasone propionate is effective in the treatment of allergic rhinitis with cough variant asthma,it can reduce the FeNO and Eos,and inhibit the expression of VCAM-1 and HMGB1,which is worthy of promotion.
NETL
NSTL
万方数据
